Company Announcements

Robust research and data from multiple abstracts predict the Cologuard® test as the top choice for screening average-risk adults 45 and older, and confirms adoption across diverse demographics

MADISON, Wis.--(BUSINESS WIRE)--Apr. 29, 2025-- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present 15 abstracts during Digestive Disease Week (DDW) 2025, taking place May 3-6, 2025, in San Diego, California. The abstracts demonstrate high adherence and strong predicted preference for the Cologuard^® test along with abstracts on additional screening programs under development. The abstracts focused on the Cologuard test include data from more than half a million patients. DDW is the premier meeting for professionals working in gastroenterology, hepatology, GI endoscopy, and gastrointestinal surgery. DDW will make abstracts available on their website on May 3.

“Exact Sciences is proud to share our latest research at DDW 2025, highlighting the effectiveness and strong predicted preference for Cologuard, reinforcing our continued leadership in CRC screening,” said Paul Limburg, MD, MPH, AGAF, chief medical officer for Screening, Exact Sciences. “Our extensive real-world data support Cologuard as an effective screening approach for all average-risk adults ages 45 and over, across multiple demographics and patient groups. Cologuard can help address colonoscopy screening capacity constraints and improve CRC detection and prevention.”

The abstracts at DDW are as follows:

Saturday, May 3, 2025, from 4:00 PM to 5:30 PM PDT

• Patient test preferences for colorectal cancer screening: Insights from a discrete-choice experiment​
• Training and Testing of a Modified Multi-Cancer Early Detection (MCED) Blood Test Algorithm for Detection of Pancreatic Ductal Adenocarcinoma with Intended Use in High-Risk Individuals​

Sunday, May 4, 2025, from 12:30 PM to 1:30 PM PDT

• Adherence to follow-up colonoscopy after a positive stool-based test patients aged 45 to 49 years: real world differences between multitarget stool DNA testing versus fecal immunochemical or fecal occult blood testing​
• Adherence to follow-up colonoscopy after positive stool-based screening: examining differences between multitarget stool DNA tests versus fecal immunochemical or fecal occult blood tests in racial/ethnic subgroups​ ​
• Real-world adherence to follow-up colonoscopy after a positive stool-based test: examining differences between multi-target stool DNA testing versus fecal immunochemical or fecal occult blood testing by payor type​
• Adherence to FIT-based Colorectal Cancer Screening by Health Facility Type: A Systematic Review and Meta-Analysis​
• Adherence to FIT-based Colorectal Cancer Screening with and without Outreach at FQHCs and Safety-Net Facilities: A Systematic Review and Meta-Analysis​
• Adherence to Colorectal Cancer Screening with Fecal Immunochemical Testing with and Without Outreach: A Systematic Review and Meta-Analysis​
• Colorectal cancer screening with multi-targeted stool DNA test in Federally Qualified Health Center clinics​
• Adherence to multi-targeted stool DNA (mt-sDNA) test for colorectal cancer repeat screening in average-risk African American population​
• Adherence to multi-targeted stool DNA (mt-sDNA) test for colorectal cancer repeat screening in average-risk Hispanic population​
• Adherence to multi-targeted stool DNA (mt-sDNA) test for colorectal cancer repeat screening in average-risk Asian American population​
• Adherence to colorectal cancer screening using multi-target stool DNA in a large healthcare system in the northeast​

Monday, May 5, 2025, from 12:30 PM to 1:30 PM PDT

• The Environmental Impact of colorectal cancer screening with colonoscopy and mt-sDNA in the US: a simulation study​

Tuesday, May 6, 2025, from 10:15 AM to 10:30 AM PDT

• Positive and Negative Predictive Value of a Non-Endoscopic Molecular Barrett’s Esophagus Detection Test in Screening Eligible Adults: Results from a Large Multicenter Population Based Clinical Trial

Meet Exact Sciences Booth Event

Exact Sciences will host two information sessions at the company’s booth (#1819), These sessions will be led by Jordan Karlitz, senior medical officer, for Screening and Medical Affairs, Exact Sciences. The sessions will challenge assumptions about CRC screening and discuss the importance of precancer and early CRC detection. The booth sessions will take place Sunday, May 4 and Monday, May 5 at 11:30 am and 11:45 am PST.

About the Cologuard® and Cologuard Plus™ tests

Developed in collaboration with Mayo Clinic, the Cologuard® and Cologuard Plus™ tests are first-line, noninvasive colorectal cancer (CRC) screening options for adults aged 45 or older who are at average risk for the disease. The Cologuard test revolutionized CRC screening by detecting specific DNA markers and blood in stool associated with cancer and precancer, allowing patients to complete the collection kit at home without special preparation or time off, and return the kit to the lab for results. It is included in national screening guidelines from the American Cancer Society (2018) and the U.S. Preventive Services Task Force (2021). Since its inception in 2014, Cologuard has been used to screen for more CRC 19 million times.

Building on this success, the FDA-approved Cologuard Plus test raises the performance bar even further and features novel biomarkers, improved laboratory processes, and enhanced sample stability. The Cologuard Plus test is expected to reduce false positives by more than 40% compared to the original Cologuard test, helping minimize unnecessary follow-up colonoscopies. Both tests demonstrate Exact Sciences’ commitment to improving CRC screening access and outcomes.

About Exact Sciences Corp.

A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard^® and Oncotype^® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.

NOTE: Exact Sciences, Cologuard, and Cologuard Plus are trademarks of Exact Sciences Corporation. The Cologuard test and Cologuard Plus test are only available in the U.S.

Forward-Looking Statement

This news release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated.

Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements regarding the development and commercialization of the Cologuard Plus test and the performance characteristics and health care benefits of the Cologuard Plus test in a commercial setting, as well as statements regarding the development and commercialization of Exact Sciences’ pipeline tests. Risks and uncertainties that may affect our forward-looking statements are described in the Risk Factors sections of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250429379327/en/

Media Contact: Lindsey Dickinson – 608-690-0383, lidickinson@exactsciences.com
Investor Contact: Derek Leckow – 608-893-0009, investorrelations@exactsciences.com 

Source: Exact Sciences Corp.